Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 7/20 | 0.63 |
| ▸ | GABBR1 | Q9UBS5 | 7/20 | 0.63 |
| ▸ | MERTK | Q12866 | 11/20 | 0.46 |
| ▸ | AXL | P30530 | 4/20 | 0.46 |
| ▸ | TYRO3 | Q06418 | 10/20 | 0.44 |
| ▸ | FLT3 | P36888 | 8/20 | 0.44 |
| ▸ | GAS6 | Q14393 | 8/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3118159 | 0.88 | GABBR2 (0.68) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3118460 | 0.87 | GABBR2 (0.53) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3115529 | 0.84 | GABBR2 (0.55) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3121999 | 0.83 | PDE4A (0.45) | GABBR2GABBR1MERTKTYRO3FLT3 | |
| SCHEMBL3116087 | 0.82 | GABBR2 (0.74) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3114668 | 0.80 | GABBR2 (0.71) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3118347 | 0.80 | GABBR2 (0.71) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3116652 | 0.80 | GABBR2 (0.75) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3113894 | 0.80 | GABBR2 (0.71) | GABBR2GABBR1MERTKAXLTYRO3 | |
| SCHEMBL3117412 | 0.80 | GABBR2 (0.70) | GABBR2GABBR1MERTKAXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-15 | — | — | US | disclosed |
| CN-101193868-A | Pyrimidine derivatives for the treatment of GABA B mediated nervous system disorders | NOVARTIS AG (CH) | 2008-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179127-A1 | PYRIMIDINE DERIVATIVES | DPYD, NUDT1, HPRT1 | GABBR2 1611/4885GABBR1 1499/4885MERTK 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.